# Contents

## 1 New Drug Development

- **1.1 Introduction** ........................................ 1
- **1.2 Origin and Goals of the Book** ...................... 2
- **1.3 The Discipline of Statistics** ........................ 2
- **1.4 A Lifecycle Perspective on Drug Development** .... 3
- **1.5 Design, Conduct, and Analysis** ..................... 4
  - **1.5.1 Compelling Evidence** ............................ 4
- **1.6 Drug Discovery** ....................................... 4
- **1.7 Nonclinical Development Programs** ............... 5
- **1.8 Clinical Development Programs** .................... 5
  - **1.8.1 Ethical Conduct** ................................ 6
  - **1.8.2 Different Studies in a Clinical Development** .... 7
- **1.9 Manufacturing** ........................................ 8
- **1.10 Definitions of Clinical Research and Clinical Trials** .... 9
  - **1.10.1 Clinical Research** .............................. 9
  - **1.10.2 Clinical Trials** ................................ 10
- **1.11 Operational Execution** .............................. 10
- **1.12 The Central Importance of Biological Considerations** .... 10

## 2 The Regulatory Environment

- **2.1 Introduction** .......................................... 11
- **2.1.1 Goals of the ICH** ................................ 12
- **2.2 The Food and Drug Administration** ............... 12
  - **2.2.1 The Code of Federal Regulations** ............. 13
- **2.3 cGMP, cGLP, and cGCP** ................................ 14
- **2.4 Regulatory Aspects of New Drug Development** .... 14
- **2.5 Sponsor and Regulatory Agency Responsibilities** ... 15
- **2.6 The Investigational New Drug Application** ....... 15
  - **2.6.1 Review of the Investigational New Drug** ....... 17
2.7 The New Drug Application ........................................ 19
    2.7.1 Statistical Review of the New Drug Application ...... 19
Further Readings .................................................. 20

3 Drug Discovery .................................................. 21
    3.1 Introduction ................................................ 21
        3.1.1 Small Molecule Drug Candidates ....................... 21
        3.1.2 Biopharmaceutical Drug Candidates ................... 22
    3.2 Overview of Pharmaceutics, Pharmacokinetics, and Pharmacodynamics ............................................ 22
        3.2.1 Drug Receptors ......................................... 23
        3.2.2 The Pharmacodynamic Phase .......................... 23
        3.2.3 The Pharmacokinetic Phase ............................ 24
        3.2.4 The Pharmaceutical Phase ............................... 25
    3.3 Medicinal Chemistry .......................................... 25
        3.3.1 Drug Molecules ......................................... 26
        3.3.2 Macromolecules, Receptors, and Drug Targets ....... 26
        3.3.3 Structure–Activity Considerations and Drug–Receptor Interactions ........................................ 27
    3.4 Cheminformatics, Bioinformatics, and Computer-Aided Molecular Design ...................................... 28
        3.4.1 Bioinformatics ........................................... 29
    3.5 Biologicals .................................................... 30
        3.5.1 Molecular Genetics and Proteins ....................... 30
        3.5.2 Protein Structures ....................................... 31
        3.5.3 Recombinant DNA Technology ......................... 31
        3.5.4 Recombinant Proteins As Drugs ....................... 32
        3.5.5 Discovery and Development of Biopharmaceuticals .................................................. 33
    3.6 Moving to Nonclinical Research ............................. 34
Further Readings .................................................. 34

4 Nonclinical Research ............................................. 35
    4.1 Introduction ................................................ 35
        4.1.1 Reduction, Refinement, and Replacement of Laboratory Animal Studies .................................... 35
    4.2 Pharmacokinetics ............................................. 36
        4.2.1 Absorption .............................................. 36
        4.2.2 Distribution ............................................. 37
        4.2.3 Metabolism ............................................. 37
        4.2.4 Elimination ............................................. 38
    4.3 Pharmacology ................................................ 38
        4.3.1 Research Pharmacology Studies ....................... 38
        4.3.2 Safety Pharmacology Studies ........................... 39
    4.4 Toxicological Studies ........................................ 39
        4.4.1 Toxicodynamics ......................................... 40
### 4.4.2 Exploratory Toxicology Studies
- Page 40

### 4.4.3 Pre-FIH Regulatory Toxicology Studies
- Page 41

### 4.4.4 Post-FIH Regulatory Toxicology Studies
- Page 41

### 4.4.5 Dose Range-Finding Toxicology
- Page 41

### 4.4.6 Genotoxicity
- Page 42

### 4.5 Assessment of QT Interval Prolongation
- Page 42

#### 4.5.1 Long QT Syndrome: Underlying Molecular Biology
- Page 43

#### 4.5.2 Drug-Induced QT Interval Prolongation
- Page 44

#### 4.5.3 Associated Nonclinical Testing
- Page 45

#### 4.5.4 Short QT Syndrome
- Page 45

### Further Readings
- Page 46

### 5 Designing Clinical Trials
- Page 47

#### 5.1 Introduction
- Page 47

#### 5.2 Classification of Clinical Trials
- Page 47

#### 5.3 Human Pharmacology Trials
- Page 49

#### 5.4 Clinical Pharmacokinetics and Pharmacodynamics
- Page 51

##### 5.4.1 Pharmacokinetic Parameters
- Page 52

##### 5.4.2 Fasting and Fed Pharmacokinetics
- Page 52

##### 5.4.3 Absorption and Bioavailability
- Page 53

##### 5.4.4 Distribution
- Page 54

##### 5.4.5 Metabolism
- Page 54

##### 5.4.6 Elimination/Clearance
- Page 55

#### 5.5 Therapeutic Exploratory Trials
- Page 55

#### 5.6 Therapeutic Confirmatory Trials
- Page 56

#### 5.7 Therapeutic-Use Trials
- Page 56

#### 5.8 Study Design
- Page 56

#### 5.9 Ethical Aspects of Design
- Page 57

#### 5.10 Study Design in Drug Clinical Trials
- Page 57

##### 5.10.1 The Parallel Group Design
- Page 58

##### 5.10.2 The Cross-over Design
- Page 59

##### 5.10.3 Respective Advantages of the Parallel Group and Cross-over Designs
- Page 59

##### 5.10.4 Focus on the Parallel Group Design in This Book
- Page 60

#### 5.11 Central Principles of Experimental Design in Clinical Trials
- Page 60

##### 5.11.1 Replication
- Page 61

##### 5.11.2 Randomization
- Page 61

##### 5.11.3 Local Control
- Page 64

##### 5.11.4 Good Design Simplifies and Validates the Accompanying Analyses
- Page 64

##### 5.11.5 Sample Size Estimation
- Page 65
<table>
<thead>
<tr>
<th>5.12</th>
<th>The Clinical Study Protocol</th>
<th>65</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.12.1</td>
<td>Inclusion and Exclusion Criteria</td>
<td>66</td>
</tr>
<tr>
<td>5.12.2</td>
<td>The Primary Objective</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>Further Readings</td>
<td>67</td>
</tr>
<tr>
<td>6</td>
<td>Conducting Clinical Trials I: Experimental Methodology</td>
<td>69</td>
</tr>
<tr>
<td>6.1</td>
<td>Introduction</td>
<td>69</td>
</tr>
<tr>
<td>6.2</td>
<td>Blood Pressure Measurement in Clinical Trials</td>
<td>70</td>
</tr>
<tr>
<td>6.2.1</td>
<td>Hypertension</td>
<td>70</td>
</tr>
<tr>
<td>6.2.2</td>
<td>Surrogate Endpoints in Clinical Trials</td>
<td>71</td>
</tr>
<tr>
<td>6.2.3</td>
<td>Arterial Blood Pressure</td>
<td>72</td>
</tr>
<tr>
<td>6.2.4</td>
<td>Assessing Blood Pressure Change over Time</td>
<td>73</td>
</tr>
<tr>
<td>6.2.5</td>
<td>A Cautionary Tale: Blood Pressure Measurement at Your Doctor’s Office</td>
<td>74</td>
</tr>
<tr>
<td>6.2.6</td>
<td>A Cautionary Tale for Clinical Trial Blood Pressure Measurements</td>
<td>75</td>
</tr>
<tr>
<td>6.3</td>
<td>Central Labs</td>
<td>75</td>
</tr>
<tr>
<td>6.3.1</td>
<td>Operational Considerations</td>
<td>76</td>
</tr>
<tr>
<td>6.4</td>
<td>Core ECG Labs</td>
<td>77</td>
</tr>
<tr>
<td>6.5</td>
<td>The Case Report Form</td>
<td>77</td>
</tr>
<tr>
<td></td>
<td>Further Readings</td>
<td>78</td>
</tr>
<tr>
<td>7</td>
<td>Conducting Clinical Trials II: Operational Execution</td>
<td>79</td>
</tr>
<tr>
<td>7.1</td>
<td>Introduction</td>
<td>79</td>
</tr>
<tr>
<td>7.2</td>
<td>The Outsourcing Process</td>
<td>80</td>
</tr>
<tr>
<td>7.3</td>
<td>Feasibility Evaluations</td>
<td>80</td>
</tr>
<tr>
<td>7.3.1</td>
<td>More Extensive Feasibility Evaluations</td>
<td>81</td>
</tr>
<tr>
<td>7.3.2</td>
<td>Feasibility Reporting</td>
<td>82</td>
</tr>
<tr>
<td>7.4</td>
<td>Standard Operating Procedures</td>
<td>82</td>
</tr>
<tr>
<td>7.4.1</td>
<td>Balancing the Degree of Flexibility Within an SOP</td>
<td>83</td>
</tr>
<tr>
<td>7.4.2</td>
<td>The Necessity of Implementing and Maintaining SOPs</td>
<td>83</td>
</tr>
<tr>
<td>7.5</td>
<td>Project Management</td>
<td>84</td>
</tr>
<tr>
<td>7.6</td>
<td>Site and Investigator Recruitment</td>
<td>85</td>
</tr>
<tr>
<td>7.6.1</td>
<td>Principal Investigators</td>
<td>85</td>
</tr>
<tr>
<td>7.6.2</td>
<td>Responsibilities of Principal Investigators</td>
<td>86</td>
</tr>
<tr>
<td>7.6.3</td>
<td>Potential Principal Investigators in Private Practice Settings</td>
<td>86</td>
</tr>
<tr>
<td>7.6.4</td>
<td>Potential Principal Investigators at Larger Medical Institutions</td>
<td>86</td>
</tr>
<tr>
<td>7.6.5</td>
<td>Principal Investigator Training</td>
<td>87</td>
</tr>
<tr>
<td>7.7</td>
<td>Subject Recruitment and Retention</td>
<td>88</td>
</tr>
<tr>
<td>7.7.1</td>
<td>Subject Recruitment</td>
<td>88</td>
</tr>
<tr>
<td>7.7.2</td>
<td>Subject Retention</td>
<td>89</td>
</tr>
<tr>
<td>Page</td>
<td>Section</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>7.8</td>
<td>Monitoring Clinical Trials</td>
<td>90</td>
</tr>
<tr>
<td>7.9</td>
<td>Data Management</td>
<td>91</td>
</tr>
<tr>
<td>7.9.1</td>
<td>Data Management Plans</td>
<td>91</td>
</tr>
<tr>
<td>7.9.2</td>
<td>Electronic Data Capture</td>
<td>92</td>
</tr>
<tr>
<td>7.9.3</td>
<td>Database Development</td>
<td>92</td>
</tr>
<tr>
<td>7.10</td>
<td>A New Paradigm: Allying With Sponsors</td>
<td>93</td>
</tr>
<tr>
<td>7.11</td>
<td>Underperforming and Non-performing Clinical Trial Sites</td>
<td>93</td>
</tr>
<tr>
<td>7.11.1</td>
<td>Limitations of the Current Model</td>
<td>95</td>
</tr>
<tr>
<td>7.12</td>
<td>Another New Paradigm: The Site-Specific CRO</td>
<td>95</td>
</tr>
<tr>
<td>7.12.1</td>
<td>Synergies of a Sponsor CRO and a Site-Specific CRO Working Together</td>
<td>96</td>
</tr>
<tr>
<td>Further Readings</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Statistical Analysis</td>
<td>99</td>
</tr>
<tr>
<td>8.1</td>
<td>Introduction</td>
<td>99</td>
</tr>
<tr>
<td>8.2</td>
<td>Types of Clinical Data</td>
<td>100</td>
</tr>
<tr>
<td>8.2.1</td>
<td>Numerical Variables</td>
<td>100</td>
</tr>
<tr>
<td>8.2.2</td>
<td>Categorical Variables</td>
<td>100</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Parametric Tests and Nonparametric Tests</td>
<td>101</td>
</tr>
<tr>
<td>8.3</td>
<td>Descriptive Statistics: Summarizing Data</td>
<td>101</td>
</tr>
<tr>
<td>8.3.1</td>
<td>Measures of Central Tendency</td>
<td>101</td>
</tr>
<tr>
<td>8.3.2</td>
<td>Measures of Dispersion Around a Central Value</td>
<td>102</td>
</tr>
<tr>
<td>8.4</td>
<td>Inferential Statistics: Hypothesis Testing</td>
<td>103</td>
</tr>
<tr>
<td>8.4.1</td>
<td>The Search for Compelling Evidence</td>
<td>103</td>
</tr>
<tr>
<td>8.4.2</td>
<td>Variation and Systematic Variation</td>
<td>103</td>
</tr>
<tr>
<td>8.4.3</td>
<td>Between-Groups Variation and Within-Groups Variation</td>
<td>104</td>
</tr>
<tr>
<td>8.4.4</td>
<td>Comparing Between-Groups Variance and Within-Groups Variance</td>
<td>104</td>
</tr>
<tr>
<td>8.4.5</td>
<td>The Term Error Does Not Imply a Mistake</td>
<td>105</td>
</tr>
<tr>
<td>8.5</td>
<td>Probability</td>
<td>105</td>
</tr>
<tr>
<td>8.5.1</td>
<td>Likely Events Do Not Always Happen</td>
<td>106</td>
</tr>
<tr>
<td>8.5.2</td>
<td>Clinical Decision-Making</td>
<td>106</td>
</tr>
<tr>
<td>8.5.3</td>
<td>Sampling Theory</td>
<td>107</td>
</tr>
<tr>
<td>8.5.4</td>
<td>The Standard Error of the Mean</td>
<td>107</td>
</tr>
<tr>
<td>8.6</td>
<td>The Normal Distribution</td>
<td>108</td>
</tr>
<tr>
<td>8.6.1</td>
<td>Area Under the Normal Curve</td>
<td>110</td>
</tr>
<tr>
<td>8.6.2</td>
<td>Various Areas Under the Normal Curve</td>
<td>111</td>
</tr>
<tr>
<td>8.7</td>
<td>Analysis of Association</td>
<td>111</td>
</tr>
<tr>
<td>8.7.1</td>
<td>Direction of an Association</td>
<td>112</td>
</tr>
<tr>
<td>8.7.2</td>
<td>Degree of Closeness of an Association</td>
<td>112</td>
</tr>
<tr>
<td>8.7.3</td>
<td>Correlation Coefficients</td>
<td>112</td>
</tr>
<tr>
<td>8.7.4</td>
<td>Determining the Significance of a Product Moment Coefficient</td>
<td>113</td>
</tr>
</tbody>
</table>
8.7.5 The Coefficient of Determination .................. 113
8.7.6 Association Does Not Necessarily Equate to Causation .................. 114

9 Statistical Significance .............................................. 115
9.1 Introduction .................................................. 115
9.2 Creating a Research Question and Associated Hypotheses .......... 115
  9.2.1 The Research Hypothesis .................................. 115
  9.2.2 The Null Hypothesis ...................................... 116
9.3 Precise Expression of the Research Hypothesis and the Null Hypothesis: The Concept of Statistical Significance ........ 116
9.4 Hypothesis Testing ............................................. 117
9.5 Conducting a Statistical Test and Obtaining a Test Statistic ............. 118
9.6 The Independent Groups \( t \)-Test .................................. 118
  9.6.1 Degrees of Freedom ....................................... 119
  9.6.2 Format of Results from an Independent Groups \( t \)-Test ................. 120
  9.6.3 The \( p \)-Value: Its Definition and Meaning .................. 121
  9.6.4 The \( p \)-Value and Hypothesis Testing ...................... 122
  9.6.5 Two More Examples of Results from an Independent Groups \( t \)-Test ......... 122
9.7 The Dependent Measures \( t \)-Test ................................ 123
9.8 Analysis of Variance ............................................. 125
9.9 One-Factor Independent Groups ANOVA .......................... 125
  9.9.1 The Test Statistic in ANOVA ................................ 126
  9.9.2 Calculation of the \( F \)-Test ................................. 126
  9.9.3 A Further Analytical Step: Multiple Comparisons ................. 128
9.10 General Comments on Multiple-Comparison Testing ...................... 130
  9.10.1 Type I Errors and Type II Errors ......................... 130
9.11 Possible Clinical Interpretations of Statistical Results ................ 132

10 Clinical Significance .............................................. 135
10.1 Introduction .................................................. 135
10.2 The Logic of Confidence Intervals ................................ 135
10.3 Confidence Intervals for a Sample Mean .......................... 136
  10.3.1 A More Precise Definition of a Confidence Interval ............... 137
10.4 Confidence Intervals for the Difference Between Treatment Group Means ....... 137
10.5 Relationship of the 95% CI and 99% CI to the 0.05 and 0.01 \( p \)-Values .............. 138
10.6 The Additional Benefit of Using Confidence Intervals ................. 139
  10.6.1 Clinical Relevance and Clinically Relevant Differences ............. 139
11 Sample Size Estimation
11.1 Introduction ........................................ 143
11.2 Ethical Issues in Sample Size Estimation .......... 144
11.3 Variables Involved in Sample Size Estimation .... 145
11.4 Type I and Type II Errors ............................ 146
   11.4.1 The Implications of Type I and Type II Errors ... 146
11.5 Choosing the Variables Needed for Sample Size Estimation ....................................... 147
   11.5.1 Alpha and Beta ................................. 147
   11.5.2 The Treatment Effect, Its Variance, and the Standardized Treatment Effect ................. 148
11.6 Using the Appropriate Formula to Yield the Sample Size ......................................... 148
11.7 Influences on the Sponsor’s Choice of These Values .................................................. 149
11.8 Choosing the Objective(s) on Which to Base the Sample Size Estimation ..................... 150
11.9 Other Issues to Keep in Mind .......................... 150

12 General Safety Assessments .................................. 153
12.1 Introduction ........................................ 153
12.2 Operationalizing the Term Drug Safety ............... 153
   12.2.1 Perspectives of Regulators and Prescribing Physicians on Safety Data .................... 154
12.3 General Safety Assessments ............................. 155
   12.3.1 Extent of Exposure ............................... 156
   12.3.2 Adverse Events .................................. 156
   12.3.3 Common Laboratory Tests ....................... 157
   12.3.4 Vital Signs ...................................... 159
12.4 Acquisition and Management of Safety Data ........... 159
   12.4.1 Adverse Events .................................. 159
   12.4.2 Serious Adverse Event Data ..................... 160
12.5 Analysis Populations .................................... 161
12.6 Presentation of Safety Data ............................. 161
   12.6.1 Descriptive Approaches to Safety Data .......... 162
   12.6.2 Time-to-Event Analysis .......................... 163
   12.6.3 Differences Between Approaches to Safety and Efficacy Data .............................. 164
Further Readings ........................................... 164

13 Efficacy Assessment ........................................... 165
13.1 Introduction .......................................... 165
   13.1.1 Superiority, Equivalence, and Noninferiority Trials ............................................. 165
   13.1.2 Group Sequential and Adaptive Study Designs ................................................. 166
13.2 Analysis Populations .................................... 166
   13.2.1 The Intent-to-Treat Population .................. 167
   13.2.2 The Per-protocol Population ...................... 167
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.2.3 Using Both Analysis Populations</td>
<td>167</td>
</tr>
<tr>
<td>13.2.4 Missing Data</td>
<td>168</td>
</tr>
<tr>
<td>13.3 Hypothesis Testing Is Integral to All of the Designs Discussed</td>
<td>168</td>
</tr>
<tr>
<td>13.4 Superiority Trials</td>
<td>169</td>
</tr>
<tr>
<td>13.4.1 Well-Defined Study Objectives and Endpoints</td>
<td>169</td>
</tr>
<tr>
<td>13.4.2 Analysis of Covariance</td>
<td>170</td>
</tr>
<tr>
<td>13.4.3 Subgroup Analysis</td>
<td>171</td>
</tr>
<tr>
<td>13.5 Equivalence Trials</td>
<td>172</td>
</tr>
<tr>
<td>13.5.1 Why the Hypothesis Testing Strategy Is Different Here</td>
<td>173</td>
</tr>
<tr>
<td>13.5.2 Establishing the Equivalence Margin</td>
<td>174</td>
</tr>
<tr>
<td>13.5.3 Hypothesis Construction and Testing</td>
<td>175</td>
</tr>
<tr>
<td>13.5.4 Statistical Analysis and Clinical Judgment Working Together</td>
<td>176</td>
</tr>
<tr>
<td>13.6 Noninferiority Trials</td>
<td>176</td>
</tr>
<tr>
<td>13.6.1 Establishing the Noninferiority Margin</td>
<td>176</td>
</tr>
<tr>
<td>13.6.2 Hypothesis Construction and Testing</td>
<td>176</td>
</tr>
<tr>
<td>13.6.3 Statistical Analysis and Clinical Judgment Working Together</td>
<td>177</td>
</tr>
<tr>
<td>13.7 Group Sequential Designs</td>
<td>177</td>
</tr>
<tr>
<td>13.7.1 Interim Analyses in Group Sequential Trials</td>
<td>178</td>
</tr>
<tr>
<td>13.7.2 Data Monitoring Committees</td>
<td>178</td>
</tr>
<tr>
<td>13.7.3 Statistical Methodology for Interim Analysis</td>
<td>179</td>
</tr>
<tr>
<td>13.7.4 Ethical Considerations in Early Termination</td>
<td>182</td>
</tr>
<tr>
<td>13.8 Adaptive Designs</td>
<td>183</td>
</tr>
<tr>
<td>13.8.1 Protocol Amendments</td>
<td>183</td>
</tr>
<tr>
<td>13.8.2 Increasing Awareness of Adaptive Designs</td>
<td>184</td>
</tr>
<tr>
<td>13.8.3 Regulatory Guidance for Adaptive Designs</td>
<td>185</td>
</tr>
<tr>
<td>13.9 Bayesian Approaches to Analyzing Clinical Trials</td>
<td>186</td>
</tr>
<tr>
<td>13.10 Meta-analysis</td>
<td>186</td>
</tr>
<tr>
<td>13.10.1 Introduction to Meta-analysis</td>
<td>187</td>
</tr>
<tr>
<td>13.10.2 The Basic Steps</td>
<td>188</td>
</tr>
<tr>
<td>13.10.3 Choice of the Summary Statistic</td>
<td>189</td>
</tr>
<tr>
<td>Representing the Treatment Effect of Interest</td>
<td>189</td>
</tr>
<tr>
<td>13.10.4 Data Analysis</td>
<td>191</td>
</tr>
<tr>
<td>13.10.5 Evaluating Robustness</td>
<td>191</td>
</tr>
<tr>
<td>13.10.6 Dissemination of Results and Conclusions of a Meta-analysis</td>
<td>191</td>
</tr>
<tr>
<td>13.11 Therapeutic Use Trials</td>
<td>192</td>
</tr>
<tr>
<td>13.11.1 Large Simple Therapeutic Trials</td>
<td>192</td>
</tr>
<tr>
<td>Further Readings</td>
<td>193</td>
</tr>
</tbody>
</table>

14 Cardiac and Cardiovascular Safety Assessments                        | 195  |
14.1 Introduction                                                        | 195  |
14.2 A Three-Component Risk Exclusion Model                              | 196  |
14.2.1 Confidence Intervals Facilitate the Determination of Thresholds of Regulatory Concern. 197
14.3 Cardiac Safety Assessment: A Brief History. 198
14.4 Obtaining QTc Data from QT Measurements. 199
14.5 The Thorough QT/QTc Study
  14.5.1 Design of the TQT Study. 200
  14.5.2 TQT Study Conduct. 201
  14.5.3 Statistical Analysis. 202
  14.5.4 Ramifications of Interpretations by Sponsors and Regulatory Agencies. 203
14.6 FDA Guidance on Excluding Unacceptable Cardiovascular Risk in the Development of Antidiabetic Drugs for Type 2 Diabetes Mellitus. 204
  14.6.1 Clinical Trials to Be Conducted. 204
  14.6.2 Choice of Subject Populations. 205
  14.6.3 Choice of Cardiovascular Endpoints. 205
  14.6.4 Endpoint Adjudication. 205
  14.6.5 The Required Meta-analysis. 206
  14.6.6 A Dedicated Large (Simple) Cardiovascular Trial. 207
  14.6.7 An Additional Consideration for Safety Meta-analyses. 208
14.7 An Example of a Real Safety Meta-analysis. 208
14.8 Potential Regulatory Thresholds of Interest for Other Cardiovascular Parameters. 209
Further Readings. 210

15 Manufacturing Small Molecule Drugs and Biologicals 211
15.1 Introduction. 211
15.2 Nonclinical Development. 212
15.3 Drug Products for Clinical Trials
  15.3.1 Need for the Investigative Drug and the Control Drug. 213
  15.3.2 Blinding of Drug Products for Clinical Trials. 213
  15.3.3 Packaging and Distributing Clinical Drug Products. 214
15.4 Commercial Manufacturing. 215
15.5 Quality Control: Building Quality into the Process. 215
15.6 Stability Studies. 216
15.7 Immediate Release and Modified Release Tablets and Capsules. 216
15.8 Recombinant Protein Biologicals. 217
  15.8.1 Commercial-Scale Manufacturing. 218
Further Readings. 219
# Postmarketing Surveillance

16.1 Introduction ............................................. 221
16.2 Limitations of Preapproval Clinical Trials ................. 222
16.3 Individual Differences in Drug Response .................... 223
  16.3.1 Hepatic Impairment ................................. 223
  16.3.2 Renal Insufficiency ................................. 224
  16.3.3 The Elderly ........................................ 224
  16.3.4 Pediatric Populations ............................... 225
16.4 Postmarketing Surveillance ................................ 226
16.5 The 2005 CDER Report to the Nation ....................... 227
16.6 The Institute of Medicine’s 2006 Report on Drug Safety ... 228
16.7 The Food and Drug Administration Amendments Act of 2007 ............................................. 229
16.8 The FDA’s 2008 Sentinel Initiative ........................ 230
  16.8.1 The Science of Safety ............................... 230
  16.8.2 Active Surveillance .................................. 231
Further Readings ............................................ 231

# Main Themes and Concluding Comments

17.1 Introduction ............................................. 233
17.2 Ethical Considerations ................................... 234
17.3 Design, Methodology, Operations, and Analysis .......... 235
  17.3.1 Reducing Bias and Improving Precision ................ 235
  17.3.2 Our Definition of Statistics Revisited ............... 236
  17.3.3 Numerical Representations of Biological Information ............................................. 236
  17.3.4 Some Thoughts on the \( p \)-Value .................. 237
17.4 Confidence Intervals and Clinical Significance ............ 238
17.5 Pharmacokinetics and Pharmacodynamics .................... 238
17.6 Decision-Making ......................................... 239
  17.6.1 The Subjective Nature of Many Decisions .......... 239
  17.6.2 Determining Thresholds of Regulatory Concern ...... 241
17.7 Benefit–Risk Considerations ................................ 241
17.8 Biological Considerations Pervade Our Discussions ........ 241
  17.8.1 Biological Underpinnings of Precision Medicine .... 242
  17.8.2 Pharmacogenetics .................................... 242
  17.8.3 Pharmacogenomics ................................... 243
  17.8.4 Pharmacoproteomics ................................. 243
17.9 Integrated Pharmaceutical Medicine ........................ 244
17.10 Concluding Comments ................................... 245

References ..................................................... 247

Index .......................................................... 251
New Drug Development
An Introduction to Clinical Trials: Second Edition
Turner, J.R.
2010, XXV, 256 p., Hardcover